Triggering of toll-like receptor-4 in human multiple myeloma cells promotes proliferation and alters cell responses to immune and chemotherapy drug attack.

abstract：:Obesity is considered one of the risk factors for many cancers. Serum leptin levels are often elevated in obese people. Leptin has been reported to act as a mitogenic agent and promote renal cancer cell proliferation, whereas the detailed mechanisms still remain to be elucidated. The purpose of this study is to invest...

journal_title：Cancer biology & therapy

authors： Li L,Gao Y,Zhang LL,He DL

更新日期：2008-11-01 00:00:00

abstract：:Tumor growth is often associated with insufficient apoptosis. The Tumor Necrosis Factor (TNF)-Related Apoptosis-Inducing Ligand (TRAIL) and its proapoptotic receptors death receptor 4 (DR4) and DR5 agonistic monoclonal antibodies are being developed as targeted therapeutics because they kill cancer cells while sparing...

journal_title：Cancer biology & therapy

authors： Zhou L,Wang W,Dicker DT,Humphreys RC,El-Deiry WS

更新日期：2011-08-15 00:00:00

abstract：:Nucleophosmin (NPM)/B23, a multifunctional nucleolar protein, is overexpressed in actively proliferating cells and cancer cells. B23 is a tumor marker and exerts its oncogenic effect through binding and suppressing numerous tumor suppressors. NPM-ALK, an aberrant fusion protein produced from t(2;5) translocation in an...

journal_title：Cancer biology & therapy

authors： Ye K

更新日期：2005-09-01 00:00:00

abstract：:Bevacizumab, is a humanized monoclonal antibody to vasculo-endothelial-growth-factor, with anticancer activity in non-small-cell-lung cancer (NSCLC) patients. Our previous results from a dose/finding phase I trial in NSCLC patients, demonstrated the anti-angiogenic effects and toxicity of a newest bevacizumab-based co...

journal_title：Cancer biology & therapy

authors： Correale P,Botta C,Basile A,Pagliuchi M,Licchetta A,Martellucci I,Bestoso E,Apollinari S,Addeo R,Misso G,Romano O,Abbruzzese A,Lamberti M,Luzzi L,Gotti G,Rotundo MS,Caraglia M,Tagliaferri P

更新日期：2011-07-15 00:00:00

abstract：PURPOSE:Fibroblast Activation Protein (FAP) is a tumor fibroblast protease that has been shown to potentiate colorectal cancer growth. The clinical impact of FAP inhibition was tested using Val-boroPro (Talabostat), the first clinical inhibitor of FAP enzymatic activity, in a phase II study of patients with metastatic ...

journal_title：Cancer biology & therapy

authors： Narra K,Mullins SR,Lee HO,Strzemkowski-Brun B,Magalong K,Christiansen VJ,McKee PA,Egleston B,Cohen SJ,Weiner LM,Meropol NJ,Cheng JD

更新日期：2007-11-01 00:00:00

abstract：:We report 3 cases of durable complete response (CR) in patients with BRAF-mutated metastatic melanoma who were initially treated unsuccessfully with sequential immunotherapies (high dose interleukin 2 followed by ipilimumab with or without concurrent radiation therapy). After progression during or post immunotherapy, ...

journal_title：Cancer biology & therapy

authors： Wyluda EJ,Cheng J,Schell TD,Haley JS,Mallon C,Neves RI,Robertson G,Sivik J,Mackley H,Talamo G,Drabick JJ

更新日期：2015-01-01 00:00:00

abstract：OBJECTIVE:EphA2 overexpression predicts poor prognosis in endometrial cancer. To explore mechanisms for this association and assess its potential as therapeutic target, the relationship of EphA2 expression to markers of angiogenesis was examined using patient samples and an orthotopic mouse model of uterine cancer. EX...

journal_title：Cancer biology & therapy

authors： Merritt WM,Kamat AA,Hwang JY,Bottsford-Miller J,Lu C,Lin YG,Coffey D,Spannuth WA,Nugent E,Han LY,Landen CN,Nick AM,Stone RL,Coffman K,Bruckheimer E,Broaddus RR,Gershenson DM,Coleman RL,Sood AK

更新日期：2010-12-15 00:00:00

abstract：:The current therapy of cancer fails to completely and exclusively target tumor cells. An ideal target for cancer therapy should be expressed exclusively in tumor cells and contribute to tumorigenesis. Targeting such a candidate gene would cause cell death only in tumor cells. A cancer testis antigen, GAGE, is consider...

journal_title：Cancer biology & therapy

authors： Kular RK,Yehiely F,Deiss LP

更新日期：2010-05-15 00:00:00

abstract：:Microtubule-active drugs, including paclitaxel (Taxol, PTX), cause mitotic arrest, and this can result in apoptosis. A recently study has reported that PTX mediates apoptosis by upregulating FasL in Jurkat and MDA-231 cells. In contrast to the previous report, we found that anti-FasL antibodies failed to inhibit PTX-i...

journal_title：Cancer biology & therapy

authors： Blagosklonny MV,Robey R,Sheikh MS,Fojo T

更新日期：2002-03-01 00:00:00

abstract：:Breast cancers often have deregulated hepatocyte growth factor (HGF) and c-Met signaling that results in increased tumor growth and invasion. Elucidating the mechanism responsible for HGF/c-Met action in breast cancer progression has been difficult as c-Met communicates with a number of secondary receptors that can le...

journal_title：Cancer biology & therapy

authors： Bonine-Summers AR,Aakre ME,Brown KA,Arteaga CL,Pietenpol JA,Moses HL,Cheng N

更新日期：2007-04-01 00:00:00

abstract：:Invariant natural killer T (iNKT) cells are a distinct subset of human T cells, which expresses an invariant T cell receptor Vα24 Jα18 and recognizes glycolipid antigens in the context of CD1d molecules. iNKT cells exert pivotal regulatory roles in many immune responses, including antitumor immune responses. Alteratio...

journal_title：Cancer biology & therapy

authors： Altomare E,Fallarini S,Biaggi G,Gattoni E,Botta M,Lombardi G

更新日期：2012-07-01 00:00:00

abstract：:Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related death worldwide, and novel effective drugs against NSCLC are urgently needed. Isodon species are rich in ent-kaurane diterpenoids that have been reported to have antitumor bioactivity. Acetyl-macrocalin B (A-macB) is a novel ent-kaurane diterpen...

journal_title：Cancer biology & therapy

authors： Wang JN,Zhang ZR,Che Y,Yuan ZY,Lu ZL,Li Y,Li N,Wan J,Sun HD,Sun N,Puno PT,He J

更新日期：2018-07-03 00:00:00

abstract：:Tumor formation in immunocompetent hosts is believed to be dependent on the ability of tumor cells to evade the immune system, as suggested by the alterations of expression of the major histocompatibility complex (MHC) and related molecules in a number of cancers. Our previous serial analysis of gene expression (SAGE)...

journal_title：Cancer biology & therapy

authors： Rangel LB,Agarwal R,Sherman-Baust CA,Mello-Coelho Vd,Pizer ES,Ji H,Taub DD,Morin PJ

更新日期：2004-10-01 00:00:00

abstract：OBJECTIVES:Due to the absence of reliable and accurate biomarkers for the early detection of liver malignancy, circulating microRNAs have recently emerged as great candidates for prompt cancer identification. Therefore, the aim of this study was to investigate the potential of liver-specific circulating microRNAs as an...

journal_title：Cancer biology & therapy

authors： Mourad L,El-Ahwany E,Zoheiry M,Abu-Taleb H,Hassan M,Ouf A,Rahim AA,Hassanien M,Zada S

更新日期：2018-05-04 00:00:00

abstract：:Ovarian cancer is a silent killer, and shows early extensive tumor invasion and peritoneal metastasis. The microcirculation of most tumors includes cooperation of pre-existing vessels, intussusceptive microvascular growth, postnatal vasculogenesis, glomeruloid angiogenesis and vasculogenic mimicry (VM). VM is critical...

journal_title：Cancer biology & therapy

authors： Wang JY,Sun T,Zhao XL,Zhang SW,Zhang DF,Gu Q,Wang XH,Zhao N,Qie S,Sun BC

更新日期：2008-05-01 00:00:00

abstract：:Causes for the complex phenotypes of cancers, such as altered differentiation, invasion and metastasis, are not known, and multigenic defects are likely. In contrast, well-defined deficiencies, such as those affecting DNA-repair mechanisms and enzymatic pathways, are simple, typically caused by one or a few gene mutat...

journal_title：Cancer biology & therapy

authors： Dezentje DA,Arking DE,Kortenhorst MS,West K,Chakravarti A,Kern SE

更新日期：2009-02-01 00:00:00

abstract：:Tangeretin, a major phytochemicals in tangerine peels--an important Chinese herb, has been found to have anti-carcinogenic properties. To improve bioavailability and increase potency of tangeretin, its derivative, 5-acetyloxy-6,7,8,4'-tetramethoxyflavone (5-AcTMF), has been synthesized and shown potent inhibition of p...

journal_title：Cancer biology & therapy

authors： Li YR,Li S,Ho CT,Chang YH,Tan KT,Chung TW,Wang BY,Chen YK,Lin CC

更新日期：2016-01-01 00:00:00

abstract：:SEPT9 is a mammalian septin family member. There is growing evidence that SEPT9 plays a role in cancer. The protein product, SEPT9_V1, associates with microtubules and interacts with hypoxia-inducible factor (HIF)-1alpha, the regulated subunit of the key transcription factor HIF-1. HIF-1 transcriptional activity is th...

journal_title：Cancer biology & therapy

authors： Amir S,Mabjeesh NJ

更新日期：2007-12-01 00:00:00

abstract：:Recently, we showed that the metal chelator TPEN targets colon cancer cells through redox cycling of copper. Here, we studied the DNA damage potential of TPEN and deciphered the role of Chk1, ATM and DNA-PK in TPEN-induced toxicity in 3 human colon cancer cell lines, HCT116, SW480 and HT29. We also investigated the ro...

journal_title：Cancer biology & therapy

authors： Rahal ON,Fatfat M,Hankache C,Osman B,Khalife H,Machaca K,Muhtasib HG

更新日期：2016-11-01 00:00:00

abstract：:Docetaxel is an important anti-microtubule agent used to treat a variety of solid tumors, including breast cancer; notably, docetaxel-containing regimens improve outcomes for patients in metastatic, adjuvant, and neoadjuvant settings. However, the effectiveness of docetaxel in clinical practice can be compromised by s...

journal_title：Cancer biology & therapy

authors： Xuan L,Sun B,Meng X,Liu C,Cong Y,Wu S

更新日期：2020-11-01 00:00:00

abstract：:Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), such as gefitinib and erlotinib, are the first targeted therapy drugs approved for the treatment of advanced non-small-cell lung cancer (NSCLC). Interestingly, treatment with these small molecule, reversible EGFR-TKIs leads to more positive respo...

journal_title：Cancer biology & therapy

authors： Xu Y,Liu H,Chen J,Zhou Q

更新日期：2010-04-15 00:00:00

abstract：:The selectively oncolytic mtHSV, a HSV icp34.5 mutant with lacz gene insertion, was proved that it was targeted for treating tumors but not other organs, however, its oncolytic mechanism is under confirmation. The results showed that HeLa cells could be lysed efficiently by mtHSV in vitro. In the flow cytometry and We...

journal_title：Cancer biology & therapy

authors： Su Y,Zhu H,Xiao W,Xu Q,Zhu L,Zhang X,Wan Q,Zhou S,Du E,Xu H,Yao L,Lv S,Hu B,Liu Y,Qi Y

更新日期：2007-02-01 00:00:00

abstract：:The surprising results published by FIRE-3 revealed that the overall survival (OS) of RAS wild-type metastatic colorectal cancer (mCRC) patients treated with Cetuximab(Cmab) and FOLFIRI combination was prolonged to 33.1 months. The substantial increase in testing and treatment costs, however, impose a considerable hea...

journal_title：Cancer biology & therapy

authors： Wen F,Yang Y,Zhang P,Zhang J,Zhou J,Tang R,Chen H,Zheng H,Fu P,Li Q

更新日期：2015-01-01 00:00:00

abstract：:The aim of this study was to examine the cytotoxicity and mechanism of apoptosis induction of verotoxin-1 (VT-1) in human glioma cell lines. VT-1 is a member of the shiga-toxin family expressed by some serotypes of Escherichia coli and Shigella dysenteriae. Shiga-toxins have been shown to induce apoptosis by binding t...

journal_title：Cancer biology & therapy

authors： Johansson D,Johansson A,Grankvist K,Andersson U,Henriksson R,Bergström P,Brännström T,Behnam-Motlagh P

更新日期：2006-09-01 00:00:00

abstract：:Rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC) accounts for 1% of lung adenocarcinoma. Although small molecule agents with RET kinase inhibitory activity such as alectinib, vandetanib, and cabozantinib have been clinically evaluated in RET-fusion-positive NSCLC, an effective mo...

journal_title：Cancer biology & therapy

authors： Fujimura T,Furugaki K,Harada N,Yoshimura Y

更新日期：2020-09-01 00:00:00

abstract：:Any drug selects for drug resistance. But super-antagonistic drug combinations can select for drug sensitivity. This has important application not only for antibacterial therapy but also for cancer therapy: to control cancer with lesser side effects and to eliminate drug-resistant cancer cells, while sparing sensitive...

journal_title：Cancer biology & therapy

authors： Blagosklonny MV

更新日期：2007-07-01 00:00:00

abstract：:We investigated the cytotoxic interactions of romidepsin, a histone deacetylase inhibitor, and lenalidomide, an immunomodulatory agent, in a T-cell lymphoma preclinical model. Hut-78 and Karpas-299 cells were treated with romidepsin and lenalidomide alone and in combination. The interaction between romidepsin and lena...

journal_title：Cancer biology & therapy

authors： Cosenza M,Civallero M,Fiorcari S,Pozzi S,Marcheselli L,Bari A,Ferri P,Sacchi S

更新日期：2016-10-02 00:00:00

abstract：:Colorectal cancer (CRC) is the third most common form of cancer. Current treatments including chemotherapy, radiotherapy and surgery are all associated with a high risk of complications and are not always successful, highlighting the need to develop new treatment strategies. The ingestion of probiotics, prebiotics or ...

journal_title：Cancer biology & therapy

authors： Geier MS,Butler RN,Howarth GS

更新日期：2006-10-01 00:00:00

abstract：:Cutaneous T-cell lymphoma (CTCL) displays immunosuppressive properties and phenotypic plasticity. The malignant T cells in CTCL can possess features of immunomodulating regulatory T cells (Treg) and IL-17-producing helper T cells (Th17) depending on the stimuli they receive from antigen presenting cells and other sour...

journal_title：Cancer biology & therapy

authors： Abraham RM,Zhang Q,Odum N,Wasik MA

更新日期：2011-12-15 00:00:00

abstract：PURPOSE:Optical coherence tomography (OCT) is a minimally invasive, depth-resolved imaging tool that can be implemented in a small diameter endoscope for imaging mouse models of colorectal cancer (CRC). In this study, we utilized ultrahigh resolution (UHR) OCT to serially image the lower colon of azoxymethane (AOM) tre...

journal_title：Cancer biology & therapy

authors： Hariri LP,Qiu Z,Tumlinson AR,Besselsen DG,Gerner EW,Ignatenko NA,Povazay B,Hermann B,Sattmann H,McNally J,Unterhuber A,Drexler W,Barton JK

更新日期：2007-11-01 00:00:00